FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2295906267> ?p ?o ?g. }

• W2295906267 endingPage "401" @default.
• W2295906267 startingPage "401" @default.
• W2295906267 abstract "Methylnaltrexone for opioid-induced constipation: review and meta-analyses for objective plus subjective efficacy and safety outcomes Waldemar Siemens, Gerhild Becker Clinic for Palliative Care, Medical Center, University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany Introduction: Opioid-induced constipation (OIC) is a frequent adverse event that impairs patients’ quality of life. This article evaluates the objective plus subjective efficacy and the safety of methylnaltrexone (MNTX) in OIC patients.Methods: Randomized controlled trials from a recent systematic review were included. In addition, a PubMed search was conducted for January 2014 to December 21, 2015. We included randomized controlled trials with adult OIC patients, MNTX as study drug, and OIC as primary outcome. Results were categorized in three outcome types: objective outcome measures (eg, time to laxation), patient-reported outcomes (eg, straining), and global burden measures (eg, constipation distress). Dichotomous meta-analyses with risk ratios (RRs) and 95% confidence intervals (CIs) were calculated using RevMan 5.3. Only comparisons between MNTX and placebo were made.Results: We included seven studies with 1,860 patients. A meta-analysis revealed that patients under MNTX had considerably more rescue-free bowel movement within 4 hours after the first dose (RR 3.74, 95% CI 2.87 to 4.86; five studies, n=938; I2=0). Results of the review indicated that patients under MNTX had a higher stool frequency and needed less time to laxation compared with placebo. Moreover, patients receiving MNTX tended to have better values in patient-reported outcomes and global burden measures. Meta-analyses on safety revealed that patients under MNTX experienced more abdominal pain (RR 2.38, 95% CI 1.75 to 3.23; six studies, n=1,412; I2=60%) but showed a nonsignificant tendency in nausea (RR 1.27, 95% CI 0.90 to 1.78; six studies, n=1,412; I2=12%) and diarrhea (RR 1.45, 95% CI 0.94 to 2.24; five studies, n=1,258; I2=45%). The incidence of MNTX-related serious adverse events was 0.2% (4/1,860).Conclusion: MNTX has been shown to be effective and safe. Future randomized controlled trials should consequently incorporate objective outcome measures, patient-reported outcomes, and global burden measures, and research the efficacy of MNTX in other populations, for example, patients under opioids after surgical procedures. Keywords: opioid-induced constipation, methylnaltrexone, patient-reported outcomes, review, meta-analysis" @default.
• W2295906267 created "2016-06-24" @default.
• W2295906267 creator A5014298532 @default.
• W2295906267 creator A5066396077 @default.
• W2295906267 date "2016-03-01" @default.
• W2295906267 modified "2023-09-23" @default.
• W2295906267 title "Methylnaltrexone for opioid-induced constipation: review and meta-analyses for objective plus subjective efficacy and safety outcomes" @default.
• W2295906267 cites W142954314 @default.
• W2295906267 cites W1493383013 @default.
• W2295906267 cites W1710046680 @default.
• W2295906267 cites W1870319372 @default.
• W2295906267 cites W1873423066 @default.
• W2295906267 cites W1945672276 @default.
• W2295906267 cites W1979645409 @default.
• W2295906267 cites W1990538516 @default.
• W2295906267 cites W1994481170 @default.
• W2295906267 cites W1999563475 @default.
• W2295906267 cites W2015296710 @default.
• W2295906267 cites W2020177517 @default.
• W2295906267 cites W2020351580 @default.
• W2295906267 cites W2021478061 @default.
• W2295906267 cites W2021543354 @default.
• W2295906267 cites W2025164140 @default.
• W2295906267 cites W2029736656 @default.
• W2295906267 cites W2040109649 @default.
• W2295906267 cites W2041380878 @default.
• W2295906267 cites W2061895294 @default.
• W2295906267 cites W2064201279 @default.
• W2295906267 cites W2085353392 @default.
• W2295906267 cites W2096266245 @default.
• W2295906267 cites W2132033835 @default.
• W2295906267 cites W2135400982 @default.
• W2295906267 cites W2137956198 @default.
• W2295906267 cites W2141948807 @default.
• W2295906267 cites W2147808981 @default.
• W2295906267 cites W2158281754 @default.
• W2295906267 cites W2159762136 @default.
• W2295906267 cites W2160873339 @default.
• W2295906267 cites W2164341191 @default.
• W2295906267 cites W2334818213 @default.
• W2295906267 cites W2396215196 @default.
• W2295906267 cites W2402823822 @default.
• W2295906267 cites W2406100280 @default.
• W2295906267 cites W2412168058 @default.
• W2295906267 cites W2916021673 @default.
• W2295906267 doi "https://doi.org/10.2147/tcrm.s80749" @default.
• W2295906267 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4795449" @default.
• W2295906267 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27042082" @default.
• W2295906267 hasPublicationYear "2016" @default.
• W2295906267 type Work @default.
• W2295906267 sameAs 2295906267 @default.
• W2295906267 citedByCount "30" @default.
• W2295906267 countsByYear W22959062672016 @default.
• W2295906267 countsByYear W22959062672017 @default.
• W2295906267 countsByYear W22959062672018 @default.
• W2295906267 countsByYear W22959062672019 @default.
• W2295906267 countsByYear W22959062672020 @default.
• W2295906267 countsByYear W22959062672021 @default.
• W2295906267 countsByYear W22959062672022 @default.
• W2295906267 crossrefType "journal-article" @default.
• W2295906267 hasAuthorship W2295906267A5014298532 @default.
• W2295906267 hasAuthorship W2295906267A5066396077 @default.
• W2295906267 hasBestOaLocation W22959062671 @default.
• W2295906267 hasConcept C126322002 @default.
• W2295906267 hasConcept C142724271 @default.
• W2295906267 hasConcept C168563851 @default.
• W2295906267 hasConcept C170493617 @default.
• W2295906267 hasConcept C197934379 @default.
• W2295906267 hasConcept C204787440 @default.
• W2295906267 hasConcept C27081682 @default.
• W2295906267 hasConcept C2780661987 @default.
• W2295906267 hasConcept C2781063702 @default.
• W2295906267 hasConcept C2781112942 @default.
• W2295906267 hasConcept C44249647 @default.
• W2295906267 hasConcept C71924100 @default.
• W2295906267 hasConcept C95190672 @default.
• W2295906267 hasConceptScore W2295906267C126322002 @default.
• W2295906267 hasConceptScore W2295906267C142724271 @default.
• W2295906267 hasConceptScore W2295906267C168563851 @default.
• W2295906267 hasConceptScore W2295906267C170493617 @default.
• W2295906267 hasConceptScore W2295906267C197934379 @default.
• W2295906267 hasConceptScore W2295906267C204787440 @default.
• W2295906267 hasConceptScore W2295906267C27081682 @default.
• W2295906267 hasConceptScore W2295906267C2780661987 @default.
• W2295906267 hasConceptScore W2295906267C2781063702 @default.
• W2295906267 hasConceptScore W2295906267C2781112942 @default.
• W2295906267 hasConceptScore W2295906267C44249647 @default.
• W2295906267 hasConceptScore W2295906267C71924100 @default.
• W2295906267 hasConceptScore W2295906267C95190672 @default.
• W2295906267 hasLocation W22959062671 @default.
• W2295906267 hasLocation W22959062672 @default.
• W2295906267 hasLocation W22959062673 @default.
• W2295906267 hasLocation W22959062674 @default.
• W2295906267 hasLocation W22959062675 @default.
• W2295906267 hasOpenAccess W2295906267 @default.
• W2295906267 hasPrimaryLocation W22959062671 @default.
• W2295906267 hasRelatedWork W1582795936 @default.
• W2295906267 hasRelatedWork W1985549592 @default.

• next